Sequenom Inc (SQNM) Files Form 4 Insider Buying : Carolyn Beaver Buys 10,000 Shares

Sequenom Inc (SQNM): Carolyn Beaver , CFO of Sequenom Inc purchased 10,000 shares on Jun 9, 2016. The Insider buying transaction was reported by the company on Jun 10, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.10 per share for a total value of $11,000.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 10, 2016, Carolyn Beaver (CFO) purchased 10,000 shares at $1.10 per share price.On Jun 10, 2016, Jeffrey D Linton (Sr VP, GC & Secretary) purchased 5,000 shares at $1.10 per share price.Also, On Jun 8, 2016, Den Boom Dirk Van (CEO) purchased 40,000 shares at $1.09 per share price.On May 12, 2016, Daniel S Md Grosu (SVP & CMO) purchased 30,000 shares at $1.11 per share price.

Sequenom (SQNM) witnessed a volatile trading activity on Thursday Jun 9, 2016 and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $1.13 and reached the intraday high at $1.14. The bulls started the profit booking and pushed the shares to intraday low of $1.075. The trading session was marked by a volume range of 5,73,568 shares exchanging hands. The 52-week high of the shares is $3.46 and the 52-week low is $0.9153. The market cap of the company stands at $130 M and there are 11,92,16,003 shares in public circulation.

Sequenom Money Flow Index Chart

Sequenom Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Company’s diagnostic services are provided through its wholly owned subsidiary Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in and by Sequenom Laboratories as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of and reimbursement for its prenatal LDTs and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories’ test offerings in the prenatal market include MaterniT21 PLUS LDT HerediT CF LDT SensiGene RhD LDT VisibiliT LDT and Test Send-out Agreements.

Leave a Reply

Sequenom - Is it time to Sell?

Top Brokerage Firms are advising their investors on Sequenom. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.